Adalimumab products — Prior authorization and medical necessity
Customize your policy alerts
Sign up for all harvard pilgrim health care policy alerts
Know when harvard pilgrim health care releases new policies or updates existing guidance.
Monitor payer policy activity
This guideline governs prior authorization and medical necessity criteria for coverage of adalimumab products (including multiple biosimilars and brands) for Harvard Pilgrim and affiliated commercial products; it applies to prescribers seeking coverage for members under the listed commercial and public plan products.
Added Starjemza as a prerequisite for Crohn's disease, plaque psoriasis, psoriatic arthritis, and ulcerative colitis to support the updated ustekinumab strategy.
Simlandi moved from non-preferred to preferred status and Humira moved from preferred to non-preferred status.
Members who initiated the requested medication by self-paying do not qualify as having an established clinical response and must be reviewed against initial approval criteria.
For hidradenitis suppurativa, plaque psoriasis and psoriatic arthritis, initial approval limited to 6 months with reauthorization in 12‑month intervals; for ankylosing spondylitis, Crohn's disease, polyarticular JIA, rheumatoid arthritis, ulcerative colitis and uveitis, authorizations provided in 12‑month intervals.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.